Arrevus is a clinical-stage biotechnology company developing novel therapies for orphan diseases. Our mission is to develop therapeutics for unmet medical needs in areas with high treatment failure rates, few therapeutic options, and serious outcomes. Arrevus is advancing ARV-1801, a Phase III clinical program targeting cystic fibrosis pulmonary exacerbations. Arrevus is also advancing preclinical programs to address unmet needs in oncology and antimicrobial resistance.

Tags : #Biotechnology, #Research, #Immunomodulator, #Oncology, #Aerosol